Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aimmune Therap (AIMT)

Aimmune Therap (AIMT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,257,370
  • Shares Outstanding, K 65,450
  • Annual Sales, $ 0 K
  • Annual Income, $ -248,500 K
  • 60-Month Beta 1.76
  • Price/Sales 3,832.47
  • Price/Cash Flow N/A
  • Price/Book 12.55
Trade AIMT with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.33
  • Most Recent Earnings -1.06 on 07/30/20
  • Next Earnings Date 11/04/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.99
  • Number of Estimates 7
  • High Estimate -0.88
  • Low Estimate -1.23
  • Prior Year -1.03
  • Growth Rate Est. (year over year) +3.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.21 +0.82%
on 09/14/20
34.59 -0.29%
on 10/09/20
+0.29 (+0.85%)
since 09/11/20
3-Month
11.82 +191.79%
on 08/28/20
34.59 -0.29%
on 10/09/20
+18.81 (+119.96%)
since 07/10/20
52-Week
10.09 +241.82%
on 03/17/20
37.00 -6.78%
on 01/16/20
+9.94 (+40.49%)
since 10/11/19

Most Recent Stories

More News
Aimmune Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit: Portnoy Law Firm

Investors with losses are encouraged to contact the firm before November 21, 2020; click here to submit trade information

NSRGY : 111.4600 (+0.37%)
AIMT : 34.49 (-0.29%)
Uptrend Call Working As Aimmune Therapeu Stock Rises 0.8% (AIMT)

SmarTrend identified an Uptrend for Aimmune Therapeu (NASDAQ:AIMT) on August 31st, 2020 at $34.20. In approximately 2 months, Aimmune Therapeu has returned 0.85% as of today's recent price of $34.49.

AIMT : 34.49 (-0.29%)
Uptrend Call Working As Aimmune Therapeu Stock Rises 0.8% (AIMT)

SmarTrend identified an Uptrend for Aimmune Therapeu (NASDAQ:AIMT) on August 31st, 2020 at $34.20. In approximately 2 months, Aimmune Therapeu has returned 0.85% as of today's recent price of $34.49.

AIMT : 34.49 (-0.29%)
Aimmune Receives Positive CHMP Opinion on PALFORZIA(R) for the Treatment of Patients with Peanut Allergy in Europe

Final European Commission Decision on Marketing Approval Anticipated in Q4 2020

AIMT : 34.49 (-0.29%)
Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Aimmune Therapeutics, Inc. In The Northern District Of California

, /PRNewswire/ -- Notice is hereby given that has filed a class action lawsuit in District Court for the Northern District of , Case No. 4:20-cv-06733-YGR, on behalf of common shareholders of Aimmune...

AIMT : 34.49 (-0.29%)
Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.

, /PRNewswire/ -- Société des Produits Nestlé S.A. ("Nestlé") today announced the results of the tender offer by its wholly-owned subsidiary, SPN MergerSub, Inc. ("Purchaser"), to purchase all of...

AIMT : 34.49 (-0.29%)
Life-Saving Advancements, Treatments Delivered by Companies Invested in Innovation

, /PRNewswire/ -- Innovation and breakthroughs in the biotech industry are essential to identifying and providing life-saving treatments. Companies that invest substantial amounts of time, effort, and...

KBLM : 4.99 (-17.52%)
FMCI : 24.07 (-8.06%)
AHCO : 28.91 (-1.06%)
ADAP : 4.37 (-3.96%)
AIMT : 34.49 (-0.29%)
IMVT : 48.67 (-1.44%)
CDNA : 55.64 (-6.57%)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of AIMT, BMCH, BYFC, and CGIX Mergers

EQNX::TICKER_START (NASDAQ:AIMT),(NASDAQ:BMCH),(NASDAQ:BYFC),(NasdaqGM:CGIX), EQNX::TICKER_END

AIMT : 34.49 (-0.29%)
BMCH : 48.47 (+0.81%)
BYFC : 1.7500 (+4.17%)
CGIX : 2.24 (+1.82%)
Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies

- Longitude Venture Partners IV will build on the Firm's commitment to improve clinical outcomes, enhance patient quality of life, and drive efficiency in healthcare delivery -

AIMT : 34.49 (-0.29%)
ETNB : 26.95 (-2.36%)
AXNX : 44.52 (-3.84%)
CMPI : 11.00 (+0.36%)
INZY : 26.45 (+2.36%)
MTEM : 8.79 (-2.33%)
PSTX : 11.10 (-1.07%)
PCVX : 34.60 (-0.83%)
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics, Inc. - AIMT

, /PRNewswire/ -- , founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in , is investigating Aimmune Therapeutics, Inc. ("Aimmune"...

AIMT : 34.49 (-0.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and...

See More

Key Turning Points

2nd Resistance Point 34.59
1st Resistance Point 34.54
Last Price 34.49
1st Support Level 34.46
2nd Support Level 34.43

See More

52-Week High 37.00
Last Price 34.49
Fibonacci 61.8% 26.72
Fibonacci 50% 23.55
Fibonacci 38.2% 20.37
52-Week Low 10.09

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar